SCHEMBL6673055

SCHEMBL6673055

Nc1ccc(C(=O)N2C(=O)CCC3CCCCC32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.40
L3MBTL3 Q96JM7 2/20 0.38
AVPR2 P30518 1/20 0.37
AVPR1A P37288 1/20 0.37
MGLL Q99685 1/20 0.37
CNR2 P34972 1/20 0.36
MBTD1 Q05BQ5 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HPGD P15428 3/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6670611 0.97 HSD11B1 (0.40) HSD11B1L3MBTL3AVPR2AVPR1AMGLL
SCHEMBL6670916 0.87 HSD11B1 (0.39) HSD11B1L3MBTL3MGLLCNR2MBTD1
SCHEMBL6670977 0.87 HSD11B1 (0.41) HSD11B1L3MBTL3AVPR2AVPR1AMGLL
SCHEMBL6672331 0.86 HSD11B1 (0.49) HSD11B1MGLLCNR2ALDH1A1GAA
SCHEMBL6672033 0.86 KMT2A (0.41) L3MBTL3CNR2HPGDALDH1A1GAA
SCHEMBL6670907 0.84 HSD11B1 (0.39) HSD11B1L3MBTL3MGLLCNR2MBTD1
SCHEMBL6674648 0.83 KMT2A (0.41) L3MBTL3CNR2HPGDALDH1A1MEN1
SCHEMBL6669053 0.83 HSD11B1 (0.46) HSD11B1MGLLALDH1A1GAAMEN1
SCHEMBL6670959 0.82 KDM4E (0.52) HSD11B1CNR2HPGDALDH1A1GAA
SCHEMBL6672554 0.82 NR3C2 (0.45) CA1CA2L3MBTL1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0713702-B1 ANXIOLYTIC AGENT TAIHO PHARMACEUTICAL CO LTD (JP) 2004-09-29 EP disclosed
US-6500819-B2 HAS AN EXCELLENT ANXIOLYTIC EFFECT TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 2002-12-31 US disclosed
US-20020099048-A1 Bicycloloactam compounds, use thereof and intermediates for preparing thereof TAIHO PHARMACEUTICAL COMPANY LIMITED 2002-07-25 US disclosed
US-6355668-B1 ANXIOLYTIC AGENTS; SIDE EFFECT REDUCTION TAIHO PHARMACEUTICAL CO., LTD. (JP) 2002-03-12 US disclosed
US-6303623-B1 TREATING ANXIETY IN A PATIENT IN NEED OF SUCH TREATMENT, COMPRISING ADMINISTERING BICYCLOLACTAM COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2001-10-16 US disclosed
US-6159987-A Bicyclolactam compounds, use thereof and intermediates for preparing thereof TAIHO PHARMACEUTICALS, CO. (JP) 2000-12-12 US disclosed
US-6004975-A ANXIOLYTIC AGENTS WITH SIDE EFFECT REDUCTION TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1999-12-21 US disclosed
EP-0713702-A1 ANXIOLYTIC AGENT TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1996-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099048-A1 Bicycloloactam compounds, use thereof and intermediates for preparing thereof CYP11B1, GABRA6, CYP11B2 HSD11B1 265/4885L3MBTL3 3099/4885AVPR2 928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.